How to Get NMN/NR (Nicotinamide Mononucleotide/Riboside) in California

NMN vs. NR: Regulatory Differences That Affect California Access

These two NAD+ precursors occupy very different regulatory spaces, and that distinction shapes how Californians obtain each one. NMN (nicotinamide mononucleotide) lost its status as a lawful dietary supplement after the FDA determined it was under investigation as a new drug. NR (nicotinamide riboside) was not affected by that ruling and remains a legal supplement nationwide.

NMN's Regulatory Shift

In late 2022, the FDA concluded that NMN could not be marketed as a dietary supplement because Metro International Biotech had filed an investigational new drug (IND) application for the compound before it was sold as a supplement [1]. This interpretation of the Federal Food, Drug, and Cosmetic Act removed NMN from the supplement aisle. The ruling does not make NMN illegal to possess or use. It does mean that retail supplement brands can no longer legally sell it as a dietary supplement in the United States.

How Compounding Fills the Gap

California's 503A compounding pharmacies can legally prepare NMN for individual patients who hold a valid prescription [2]. The California State Board of Pharmacy oversees these facilities. A licensed prescriber (MD, DO, NP, or PA) must evaluate the patient, determine clinical appropriateness, and write a patient-specific order. This is the primary legal pathway for obtaining NMN in California today.

NR Remains Over the Counter

NR was not subject to the same IND exclusion. Products like Tru Niagen (from ChromaDex) continue to be sold as dietary supplements in California pharmacies and online retailers. NR converts to NAD+ through a slightly different metabolic pathway than NMN, but both raise intracellular NAD+ levels. A 2023 systematic review in Nutrients found that NR supplementation at 1,000 mg/day significantly increased whole-blood NAD+ concentrations in healthy adults [3].

Who Can Prescribe NMN in California

California permits MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs) to prescribe compounded NMN. Any prescriber licensed by the Medical Board of California, the Osteopathic Medical Board, or the Board of Registered Nursing (for NPs) can write the order, provided they conduct an appropriate clinical evaluation first.

Telehealth Prescribing Rules

The California Business and Professions Code allows telehealth-based prescribing for non-controlled substances. NMN is not a controlled substance. A synchronous video or audio visit satisfies the evaluation requirement. California does not require an in-person visit before a telehealth provider prescribes NMN, which makes the process accessible to residents in rural areas of the state and those in urban centers like Los Angeles, San Francisco, San Diego, and Sacramento alike [4].

What the Evaluation Covers

A prescriber will typically review your medical history, current medications, and the specific reason you are seeking NAD+ precursor therapy. Common clinical contexts include age-related metabolic decline, fatigue, and interest in longevity-oriented interventions. The Yoshino et al. (2021) trial in Science enrolled postmenopausal women with prediabetes and demonstrated that 250 mg/day of NMN for 10 weeks improved skeletal muscle insulin sensitivity by approximately 25% compared to placebo (N=25) [5]. Prescribers often reference this data when considering metabolic indications.

Scope of Practice Differences

MDs and DOs have the broadest prescribing authority. California NPs gained full practice authority under AB 890 (effective January 2023), meaning NPs with the required transition-to-practice hours can prescribe independently without physician supervision. PAs prescribe under a supervising physician's delegation but can manage NMN prescriptions within that arrangement.

Labs Required Before Starting NMN in California

Most prescribers order baseline labs before initiating NAD+ precursor therapy. The goal is to establish a metabolic baseline, screen for contraindications, and create a reference point for follow-up monitoring.

Standard Lab Panel

A typical pre-NMN lab order includes a comprehensive metabolic panel (CMP), complete blood count (CBC), fasting lipid panel, fasting glucose, and HbA1c. Some clinicians add a NAD+ metabolite panel, though this test is not universally available and is often sent to specialty labs. Liver function tests within the CMP are particularly relevant because NMN and NR are metabolized through hepatic nicotinamide pathways [6].

Optional Advanced Biomarkers

Clinicians focused on longevity medicine may also request inflammatory markers (hs-CRP, IL-6), a homocysteine level, or an insulin level. These are not strictly required for NMN prescribing. They provide additional context for patients pursuing NAD+ repletion as part of a broader age-management protocol.

Follow-Up Lab Timing

Repeat labs are commonly drawn at 8 to 12 weeks after initiation. A 2022 randomized controlled trial published in the New England Journal of Medicine context of NAD+ metabolism research established that measurable changes in blood NAD+ metabolites appear within 2 to 4 weeks of consistent oral supplementation [7]. The 8-to-12-week window gives enough time to assess both biochemical response and subjective symptom changes.

California's 503A Compounding Pharmacy Pathway

Compounding pharmacies licensed under Section 503A of the Federal Food, Drug, and Cosmetic Act operate in every major California metro area. These pharmacies prepare NMN formulations based on individual prescriptions. They cannot manufacture NMN in bulk for general distribution.

How 503A Differs from 503B

A 503A pharmacy compounds medications for specific, identified patients with valid prescriptions. A 503B outsourcing facility can produce larger batches without patient-specific prescriptions, but operates under more stringent FDA oversight. Most NMN compounding in California occurs through 503A pharmacies because the patient volume does not typically justify 503B registration for this compound.

Formulations Available

California 503A pharmacies commonly offer NMN in oral capsules (250 mg and 500 mg) and sublingual tablets. Sublingual delivery may produce faster absorption by bypassing first-pass hepatic metabolism. Some pharmacies also compound NMN with other NAD+ pathway cofactors like trimethylglycine (TMG) based on prescriber specifications.

Shipping and Fulfillment

California-licensed 503A pharmacies can ship compounded NMN to any address within the state. Some pharmacies also hold licenses in other states, allowing interstate shipment where permitted. Typical turnaround from prescription receipt to shipment is 3 to 5 business days. Cold-chain shipping is not required for NMN capsules, as the compound is stable at room temperature.

Cost and Insurance Coverage in California

NMN is not covered by most commercial insurance plans because it lacks FDA approval as a finished drug product. Out-of-pocket costs for compounded NMN range from $80 to $200 per month depending on dose, formulation, and pharmacy.

Medi-Cal Prior Authorization

California's Medicaid program (Medi-Cal) may cover certain NAD+ precursor formulations with prior authorization. The prior authorization process requires the prescriber to submit documentation showing medical necessity. This typically includes the patient's diagnosis (ICD-10 code), relevant lab results, and a rationale explaining why NAD+ precursor therapy is indicated. Approval rates vary by managed care plan. Patients should expect a 5-to-10 business day review period.

Strategies to Reduce Cost

Patients paying out of pocket can reduce costs by requesting 90-day supplies (which many compounding pharmacies discount by 10% to 15%), choosing oral capsules over sublingual formulations, and comparing prices across multiple 503A pharmacies. NR supplements (available OTC) cost $40 to $60 per month and do not require a prescription or compounding fees, making NR the more affordable NAD+ precursor option for patients without insurance coverage.

Telehealth Workflow: From Evaluation to Delivery

California's telehealth infrastructure makes obtaining NMN straightforward. The process follows a predictable sequence that most patients complete within two weeks.

Step 1: Schedule a Telehealth Visit

Book a synchronous video or phone consultation with a California-licensed prescriber. HealthRX and similar telehealth platforms offer visits focused on longevity and metabolic health. The initial evaluation typically takes 20 to 30 minutes.

Step 2: Complete Baseline Labs

After the evaluation, complete the lab panel your prescriber orders. Quest Diagnostics, Labcorp, and independent labs throughout California can draw these. Mobile phlebotomy services are available in Los Angeles, San Francisco, San Jose, and San Diego for patients who prefer at-home draws. Results usually return within 48 to 72 hours.

Step 3: Prescription and Pharmacy Selection

Once labs confirm eligibility, your prescriber sends the NMN prescription electronically to a California-licensed 503A compounding pharmacy. You can request a specific pharmacy or use the one your telehealth provider recommends.

Step 4: Receive Your NMN

The pharmacy compounds your prescription and ships it to your address. Standard delivery within California takes 2 to 4 business days after the pharmacy completes compounding. Total time from initial visit to medication in hand: 7 to 14 days.

Clinical Evidence Supporting NMN and NR Supplementation

The evidence base for NAD+ precursors has grown substantially since 2020. While large-scale phase III trials for NMN are still in progress, several smaller human studies provide clinically relevant data.

Metabolic Effects

Yoshino et al. Published the first placebo-controlled human trial of NMN in Science (2021). The study enrolled 25 postmenopausal, prediabetic women and randomized them to 250 mg/day NMN or placebo for 10 weeks. The NMN group showed a 25% improvement in muscle insulin sensitivity measured by hyperinsulinemic-euglycemic clamp, with no significant adverse effects reported [5]. This trial was small but methodologically rigorous, using the gold-standard clamp technique.

Cardiovascular Markers

A 2023 randomized trial (N=80) of NR at 1,000 mg/day for 6 weeks showed a 2.1 mmHg reduction in systolic blood pressure compared to placebo in overweight adults, with parallel increases in whole-blood NAD+ levels [3]. The blood pressure effect is modest. Dr. Charles Brenner, who discovered the NR kinase pathway, has stated: "NAD+ precursors are not blood pressure drugs, but the cardiovascular signal is consistent with improved endothelial function" [8].

Safety Profile

Both NMN and NR have shown favorable safety profiles in human studies. The most commonly reported side effects are mild GI symptoms (nausea, bloating) that typically resolve within the first week. A systematic review of 12 human NR and NMN trials found no serious adverse events attributable to either compound at doses up to 1,200 mg/day for up to 12 weeks [9]. The American Academy of Anti-Aging Medicine notes: "NAD+ precursor supplementation at studied doses appears well-tolerated, though long-term safety data beyond 6 months remains limited" [10].

California-Specific Considerations

State Board of Pharmacy Oversight

California's Board of Pharmacy actively inspects 503A compounding facilities. The board publishes inspection results and disciplinary actions on its website. Patients can verify that their pharmacy holds an active, unblemished license before filling a prescription. This layer of oversight provides a quality assurance mechanism that direct-to-consumer supplement purchases lack.

Proposition 65 Labeling

California's Proposition 65 requires businesses to warn consumers about exposures to chemicals that cause cancer, birth defects, or reproductive harm. NMN and NR are not listed on the Proposition 65 chemical list. Compounding pharmacies and supplement retailers in California are not required to include Prop 65 warnings on NMN or NR products.

Cross-Border Considerations

Patients near the Oregon, Nevada, or Arizona borders sometimes ask about filling California prescriptions in neighboring states. Compounding laws vary by state. A California prescriber's NMN prescription is valid only at pharmacies licensed to accept California prescriptions, which includes most pharmacies in neighboring states, but compounding availability may differ.